Free Trial
Earnings Season Is Here. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion
OTCMKTS:BICX

Biocorrx Earnings Date & Estimates

Biocorrx logo
$0.21 0.00 (0.00%)
As of 10/23/2026

Biocorrx is estimated to report earnings on Tuesday, November 17, 2026.

Research:ProfileEarnings History

Upcoming Earnings Announcement

Announcement Date
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Biocorrx

Biocorrx is expected to post earnings of -$0.05 per share on revenue of $0.25 million. In the same quarter a year earlier Biocorrx reported -$0.11 per share on revenue of $0.63 million. Biocorrx last reported on August 14, 2026, posting -$0.03 per share and beating the -$0.05 consensus estimate. Biocorrx has beaten the consensus EPS estimate in 3 of its last 4 quarters.

Consensus Estimates

Consensus EPS
-$0.05
Expected Revenue
$0.25 million
Prior-Year EPS
-$0.11
Prior-Year Revenue
$0.63 million
Expected Revenue Growth
-60.3%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.03 (Beat by +$0.02)
Last Quarter Revenue
$0.09 million
EPS Beat Rate
3 of last 4 quarters

Prepare for the Earnings Call

Biocorrx Earnings FAQ

Biocorrx (OTCMKTS:BICX) is estimated to report earnings on Tuesday, November 17, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect Biocorrx to post earnings of -$0.05 per share for the quarter.

The consensus revenue estimate for Biocorrx is $0.25 million for the quarter.

Biocorrx Earnings Headlines

Biocorrx (OTCMKTS:BICX) Share Price Crosses Above Fifty Day Moving Average - What's Next?
October 21, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31141839
BioCorRx Inc. Appoints Former Acting White House Drug Policy Director Richard J. Baum to Strategic Advisory Board
September 10, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/biocorrx-inc-appoints-former-acting-091600940.html
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.tc pixel
October 25 at 1:00 AM  |  Behind the Markets (Ad)
BioCorRx Announces National Drug Codes (NDCs) for LUCEMYRA (lofexidine) Brand and Authorized Generic (AG) SKUs to Ensure Uninterrupted Market Supply
August 25, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/biocorrx-announces-national-drug-codes-121700855.html
BioCorRx Inc.
April 21, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/Stock/BICX/financials
BioCorRx, Inc. Announces Issuance of U.S. Patent Supporting Its Biodegradable Naltrexone Implant Technology
March 11, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/biocorrx-inc-announces-issuance-u-123000683.html
See More Biocorrx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biocorrx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biocorrx and other key companies, straight to your email.

About Biocorrx

Biocorrx (OTCMKTS:BICX) is a behavioral healthcare and biotechnology company focused on developing programs and products intended to support people recovering from alcohol and substance-use disorders. The company’s principal offering is the BioCorRx Recovery Program, an outpatient approach that combines counseling and behavioral support with a proprietary nutritional supplement regimen.

The company has also marketed its Start Fresh program and related products through treatment providers and other healthcare channels. BioCorRx’s business model has included licensing its treatment programs to independent providers, who deliver services to clients under the company’s program framework.

BioCorRx is based in the United States and has focused primarily on serving the domestic addiction-treatment market. Publicly available information about its current leadership, geographic reach, and operating activities is limited, so additional details cannot be reliably confirmed.

View Biocorrx Profile
Earnings Tools